Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > BioVaxys to Participate in the US Government (BARDA)
View:
Post by venturetown on Nov 06, 2024 8:13am

BioVaxys to Participate in the US Government (BARDA)

Biovaxys will collaborate with top companies like AstraZeneca, Novavax, Ginko Bioworks, and others. This puts Biovaxys at the heart of vaccine innovation. The RRPV aims to accelerate the development vaccines and therapeutics, including Biovaxys's DPX vaccine technology. This could be key in BARDA's priority vaccine programs.
Comment by javaman12 on Nov 06, 2024 4:26pm
What's potentially big here is the possibility of getting some substantial amount of funding from the US government for research. An award like that would help kick start this company to a much higher share price.  BioVaxys needs some significant capital funding and our cheap share price isn't going to get us there any time soon!  Potential shareholders want to see some bigger ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities